Akt Activation With IPL344 Treatment for Amyotrophic Lateral Sclerosis: First in Human, Open-Label Study

Marc Gotkine; David A. Schoenfeld; Ilana Cohen; Jeremy M. Shefner; Yossef Lerner; Irun R. Cohen; Colin Klein; Eran Ovadia; Merit E. Cudkowicz; the Pooled Resource Open‐Access ALS Clinical Trials Consortium

doi:10.1002/mus.28393

Back

Akt Activation With IPL344 Treatment for Amyotrophic Lateral Sclerosis: First in Human, Open-Label Study

Journal article

Open access

Peer reviewed

Akt Activation With IPL344 Treatment for Amyotrophic Lateral Sclerosis: First in Human, Open-Label Study

Marc Gotkine, David A. Schoenfeld, Ilana Cohen, Jeremy M. Shefner, Yossef Lerner, Irun R. Cohen, Colin Klein, Eran Ovadia, Merit E. Cudkowicz and the Pooled Resource Open‐Access ALS Clinical Trials Consortium

Muscle & nerve, Vol.71(6), pp.1032-1042

06/2025

DOI: https://doi.org/10.1002/mus.28393

PMID: 40105198

Abstract

Akt

amyotrophic lateral sclerosis

clinical trial

IPL344

Files and links (1)

url

https://doi.org/10.1002/mus.28393View

Published (Version of record) Open

Metrics

1 Record Views

Details

Title: Akt Activation With IPL344 Treatment for Amyotrophic Lateral Sclerosis: First in Human, Open-Label Study
Creators: Marc Gotkine - Hebrew University of Jerusalem
David A. Schoenfeld - Massachusetts General Hospital
Ilana Cohen - Mapi Pharma (Israel)
Jeremy M. Shefner - Barrow Neurological Institute
Yossef Lerner - Hebrew University of Jerusalem
Irun R. Cohen - Mapi Pharma (Israel)
Colin Klein - Meir Medical Center
Eran Ovadia - Mapi Pharma (Israel)
Merit E. Cudkowicz - Harvard University
the Pooled Resource Open‐Access ALS Clinical Trials Consortium
Publication Details: Muscle & nerve, Vol.71(6), pp.1032-1042
Number of pages: 11
Grant note: NINDS UCB AB Sciences Immunity Pharma Acorda Therapeutics ACP Clinical Communications Ltd. Cytokinetics Incorporated Biogen ALS Association
Identifiers: 991006262245902656
Academic Unit: Neurology
Language: English
Resource Type: Journal article